AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

This was the stock's second consecutive day of gains.